Tilray Tilray (TLRY) is one of the major players
Post# of 86950
(Total Views: 503)
Posted On: 01/23/2020 6:24:56 PM
Tilray
Tilray (TLRY) is one of the major players in the cannabis industry. Back in September 2018, the medical cannabis products company announced it received approval from the U.S. federal government to import a cannabinoid product for a clinical trial in California. The product is designed to address a particular type of seizure disorder. The Canadian company is reliant upon exports to foreign markets because of its focus on the medical marijuana arena, according to a report by Motley Fool. Exporting to the U.S. is crucial because the U.S. government has only one federally-approved facility to grow marijuana, meaning the flow of supplies for medical developers is excruciatingly slow.
Tilray is the first company that received approval from the U.S. Drug Enforcement Administration (DEA) to ship cannabis products into the United States. It is a highly specialized case, but represents a potential path forward for similar medical marijuana research outfits nonetheless.
Tilray was founded in 2013, and is has its main headquarters in Toronto, Canada. The company also has offices in Australia and New Zealand, Europe, and Latin America. It launched its initial public offering (IPO) in 2018, and was the first cannabis company to trade on a stock exchange in the United States. Tilray entered into an agreement with New York University in 2019 to export CBD to the school for research purposes.
Tilray (TLRY) is one of the major players in the cannabis industry. Back in September 2018, the medical cannabis products company announced it received approval from the U.S. federal government to import a cannabinoid product for a clinical trial in California. The product is designed to address a particular type of seizure disorder. The Canadian company is reliant upon exports to foreign markets because of its focus on the medical marijuana arena, according to a report by Motley Fool. Exporting to the U.S. is crucial because the U.S. government has only one federally-approved facility to grow marijuana, meaning the flow of supplies for medical developers is excruciatingly slow.
Tilray is the first company that received approval from the U.S. Drug Enforcement Administration (DEA) to ship cannabis products into the United States. It is a highly specialized case, but represents a potential path forward for similar medical marijuana research outfits nonetheless.
Tilray was founded in 2013, and is has its main headquarters in Toronto, Canada. The company also has offices in Australia and New Zealand, Europe, and Latin America. It launched its initial public offering (IPO) in 2018, and was the first cannabis company to trade on a stock exchange in the United States. Tilray entered into an agreement with New York University in 2019 to export CBD to the school for research purposes.
(0)
(0)